Smart Inhalers Market is estimated to be valued at USD 938.4 Mn in 2025 and is expected to reach USD 23,478.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 58.4% from 2025 to 2032.
The Smart Inhalers Market demand is expected to expand quickly in 2025 as more individuals are getting asthma and COPD and more people are using digital health technologies. Smart inhalers with sensors help patients stick to their treatment plans, keep track of their doses, and give healthcare providers real-time data. North America is the most popular place for adoption, and hospitals are still the main way to get the product. Smart inhalers are the best choice considering they are affordable, easy to use, and work with other connected platforms. This has led to strong growth in the global market.
|
Current Event |
Description and Its Impact |
|
Regulatory Framework Evolution and Digital Health Integration |
|
|
Technological Breakthrough in AI and Sensor Integration |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of product, the inhalers segment is expected to lead the market with 94.4% share in 2025. This is mostly as inhalers are widely used to treat asthma and chronic obstructive pulmonary disease (COPD), which remain two of the most common respiratory conditions in the world. Inhalers, especially Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs), are smaller, easier to carry, and easier for patients to use compared to nebulizers, which are larger and usually only used in hospitals or at home.
Given their design, they adapt with smart technologies. This allows sensors to keep track of dosage, inhalation technique, and patient adherence in real time. This not only leads to better treatment outcomes, but it also gives healthcare providers useful information for keeping an eye on and changing therapy. In addition, inhalers are reasonably priced, widely prescribed, and well-known to both patients and doctors, which is why they are still the most popular choice.
For instance, in March 2025, Smart Respiratory has announced a new pilot program to change the way respiratory care is done in community pharmacies. The goal of the initiative is to use smart inhaler technology to help patients stick to their treatment plans, keep an eye on their health, and manage their diseases better. The goal of the project is to give pharmacists more power to help patients with asthma and COPD by combining sensors and digital health platforms. This will lead to fewer hospital visits and better outcomes.
In terms of distribution channel, the hospitals segment is projected to account for the largest share of the market in 2025. Hospitals are the main places where people with chronic respiratory conditions get care, thus being where smart inhalers are first prescribed and provided. In a hospital, patients get the right information on usage of devices, connect sensors, and keep track of their adherence, which is important for managing their disease.
In addition, hospitals often work with device makers and digital health platforms, which speeds up the use of smart inhalers in clinical practice.
For instance, in May 2025, the University of Leicester and the University Hospitals of Leicester NHS Trust have started the first NHS study in the UK on smart inhalers for kids with asthma. The project uses the Hailie® device to keep track of how often people use their inhalers, how they use them, and how well they follow the instructions. It then shares this information with families and doctors. The goal of the program is to help people with asthma manage their condition better, have fewer flare-ups, and keep kids out of the hospital.
To learn more about this report, Download Free Sample
North America is expected to gain highest share of 35.8% in the market in 2025, due to the rise in prevalence of respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma, increase in air pollution, rise in indoor air pollutants, and increase in adoption of smart inhalers in the region. For instance, in the United States, COPD affects around 15 million adults, and many more do not know they have it. More than half of those diagnosed are women. COPD is a major cause of disability, and it is the 4th leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC).
For instance, in September 2025, Adherium's Smartinhaler shown amazing results in a real-world respiratory study carried out within the US. The program worked with Intermountain Health and CareCentra and included more than 850 patients in five facilities. The results showed that adherence was much better than what was reported in the literature. This shows that smart inhaler technology could change how asthma and COPD are treated in hospitals and clinics.
Asia Pacific is projected to be the fastest growing region, due to pollution, smoking, and urbanization are causing more asthma and COPD cases. The adoption rate is going up owing to better healthcare infrastructure, more people learning about digital health, and government programs to make respiratory care better. The region is the fastest-growing market in the world because connected medical devices are becoming more affordable and more people are investing in them.
For instance, in August 2025, PHARMAC, New Zealand’s Pharmaceutical Management Agency, announced improved access to asthma inhalers and intrauterine devices (IUDs). The move aims to make essential treatments more affordable and widely available for patients. The update is important for respiratory care, but it mostly talks about general access to inhalers instead of smart inhalers or hospital-specific programs.
The market for smart inhalers in the U.S. is going to be highly profitable in 2025 since asthma and COPD are becoming more common, digital health technologies are becoming more popular, and the FDA is approving them. North America is the world's leading region with its advanced healthcare infrastructure, the presence of major companies, and the growing focus on patient adherence and remote monitoring.
For instance, in October 2025, The FDA granted Aptar Digital Health permission to sell its connected inhaler platform in the US. The approval indicates that the company's smart inhaler technology works for managing asthma and COPD by keeping track of the frequency that patients use it and whether they follow the instructions. This milestone makes Aptar's presence in North America stronger and is a big step forward for digital respiratory care solutions.
In 2025, the market for smart inhalers in China is highly competitive as asthma and COPD are becoming more common because of pollution, smoking, and rapid urbanization. The adoption of digital health solutions is driven by the growth of healthcare infrastructure, government efforts to improve respiratory care, and more people becoming aware of them. More affordable and more investment in connected medical devices are also speeding up market growth in the area.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 938.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 58.4% | 2032 Value Projection: | USD 23,478.7 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Adherium Limited, AstraZeneca, Boehringer Ingelheim, Cohero Health, GSK, Novartis, and ResMed, among others. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
One of the key factors expected to augment the growth of the global smart inhalers market over the forecast period is the rise in prevalence of respiratory disorders worldwide. Such a high burden of respiratory diseases, such as Asthma and COPD, leads to an increase in demand for or adoption of smart inhalers worldwide.
Around 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). Moreover, COPD is the 7th leading cause of poor health worldwide (measured by disability-adjusted life years).
Another factor which is driving growth of the global smart inhalers market is the growing geriatric (aging) population around the world. For instance, the prevalence of COPD is two to three times higher in people over the age of 60 years than in younger age groups. Moreover, elderly asthmatics are at a higher risk for morbidity and mortality from their asthma than younger patients. According to the Asthma and Allergy Foundation of America, asthma is common in adults ages 65 and older, around 7.8% of older adults in the United States have asthma. That is about the same as the number of people in the general population who have asthma.
Increasing demand for smart inhalers or growing adoption of smart inhalers is expected to provide significant growth opportunities for players in the global smart inhalers market. For instance, with the rise in burden of respiratory disorders and increase in awareness among people about benefits of smart inhalers is also increasing rapidly.
As respiratory care evolves toward data-driven disease management, the smart inhalers market value is growing. More than 250 million people around the world have asthma, and only a small percentage of adults have COPD. This means that digital adherence tools have a huge user base. Clinical studies consistently indicate that 30–70% of patients fail to adhere to prescribed inhaler regimens, with incorrect usage rates surpassing 70% in certain cohorts. These numbers show how many avoidable exacerbations, emergency visits, and treatment inefficiencies connected inhalers are meant to cut down on.
Regulatory approvals for integrated digital inhalers and add-on sensors have confirmed the technology, which has led to major pharmaceutical and digital health companies launching products. There is also evidence that smart inhaler data can help with better monitoring of rescue-medication overuse, technique guidance, and earlier intervention in uncontrolled cases. This makes adoption more likely.
Definition: A smart inhaler is a medical device that integrates connectivity with a mobile app, via Bluetooth, for instance. These devices are built with sensor technology that helps record data about the time and date of use, and the location of the patient at each use.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
